基石药业-B现涨逾5% 舒格利单抗获ESMO指南非小细胞肺癌双适应症一线治疗推荐

新浪港股
11 Feb
热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易
客户端

  基石药业-B(02616)盘中一度涨超6%,截至发稿,股价上涨4.76%,现报2.64港元,成交额496.90万港元。

  基石药业昨日公布,公司重磅产品舒格利单抗(择捷美®)被纳入《欧洲肿瘤内科学会非驱动基因阳性转移性非小细胞肺癌动态临床指南》 (ESMO NonOncogene-Addicted Metastatic Non-Small-Cell Lung Cancer (NSCLC) Living Guideline) ,同时成为鳞状及非鳞状非小细胞肺癌 (鳞状NSCLC及非鳞状NSCLS)双适应症一线治疗推荐方案,具有较高的临床获益。

海量资讯、精准解读,尽在新浪财经APP

责任编辑:卢昱君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10